vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Huntington Ingalls Industries (HII). Click either name above to swap in a different company.
Huntington Ingalls Industries is the larger business by last-quarter revenue ($1.7B vs $1.1B, roughly 1.5× Elanco Animal Health Inc). Huntington Ingalls Industries runs the higher net margin — 8.9% vs -24.1%, a 33.1% gap on every dollar of revenue. On growth, Huntington Ingalls Industries posted the faster year-over-year revenue change (13.8% vs 12.2%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $-461.0M). Over the past eight quarters, Elanco Animal Health Inc's revenue compounded faster (-2.6% CAGR vs -25.2%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Huntington Ingalls Industries, Inc. (HII) is the largest military shipbuilding company in the United States as well as a provider of professional services to partners in government and industry. HII was formed on 31 March 2011, as a divestiture from Northrop Grumman.
ELAN vs HII — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.7B |
| Net Profit | $-276.0M | $149.0M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 9.3% |
| Net Margin | -24.1% | 8.9% |
| Revenue YoY | 12.2% | 13.8% |
| Net Profit YoY | -3350.0% | — |
| EPS (diluted) | $-0.55 | $3.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.1B | $3.5B | ||
| Q3 25 | $1.1B | $3.2B | ||
| Q2 25 | $1.2B | $3.1B | ||
| Q1 25 | $1.2B | $2.7B | ||
| Q4 24 | $1.0B | $3.0B | ||
| Q3 24 | $1.0B | $2.7B | ||
| Q2 24 | $1.2B | $3.0B |
| Q1 26 | — | $149.0M | ||
| Q4 25 | $-276.0M | $159.0M | ||
| Q3 25 | $-34.0M | $145.0M | ||
| Q2 25 | $11.0M | $152.0M | ||
| Q1 25 | $67.0M | $149.0M | ||
| Q4 24 | $-8.0M | $123.0M | ||
| Q3 24 | $364.0M | $101.0M | ||
| Q2 24 | $-50.0M | $173.0M |
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
| Q1 26 | — | 9.3% | ||
| Q4 25 | -22.6% | 4.9% | ||
| Q3 25 | -4.4% | 5.0% | ||
| Q2 25 | 2.0% | 5.3% | ||
| Q1 25 | 5.0% | 5.9% | ||
| Q4 24 | -5.0% | 3.7% | ||
| Q3 24 | 54.3% | 3.0% | ||
| Q2 24 | -2.7% | 6.3% |
| Q1 26 | — | 8.9% | ||
| Q4 25 | -24.1% | 4.6% | ||
| Q3 25 | -3.0% | 4.5% | ||
| Q2 25 | 0.9% | 4.9% | ||
| Q1 25 | 5.6% | 5.4% | ||
| Q4 24 | -0.8% | 4.1% | ||
| Q3 24 | 35.3% | 3.7% | ||
| Q2 24 | -4.2% | 5.8% |
| Q1 26 | — | $3.79 | ||
| Q4 25 | $-0.55 | $4.06 | ||
| Q3 25 | $-0.07 | $3.68 | ||
| Q2 25 | $0.02 | $3.86 | ||
| Q1 25 | $0.13 | $3.79 | ||
| Q4 24 | $-0.01 | $3.15 | ||
| Q3 24 | $0.73 | $2.56 | ||
| Q2 24 | $-0.10 | $4.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $216.0M |
| Total DebtLower is stronger | $3.9B | $2.7B |
| Stockholders' EquityBook value | $6.5B | $5.1B |
| Total Assets | $13.4B | $12.5B |
| Debt / EquityLower = less leverage | 0.60× | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $216.0M | ||
| Q4 25 | $545.0M | — | ||
| Q3 25 | $505.0M | — | ||
| Q2 25 | $539.0M | — | ||
| Q1 25 | $487.0M | — | ||
| Q4 24 | $468.0M | — | ||
| Q3 24 | $490.0M | — | ||
| Q2 24 | $416.0M | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $3.9B | $2.7B | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | $2.7B | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $5.1B | ||
| Q4 25 | $6.5B | $5.1B | ||
| Q3 25 | $6.7B | $5.0B | ||
| Q2 25 | $6.8B | $4.9B | ||
| Q1 25 | $6.4B | $4.8B | ||
| Q4 24 | $6.1B | $4.7B | ||
| Q3 24 | $6.5B | $4.2B | ||
| Q2 24 | $5.9B | $4.2B |
| Q1 26 | — | $12.5B | ||
| Q4 25 | $13.4B | $12.7B | ||
| Q3 25 | $13.6B | $12.3B | ||
| Q2 25 | $13.7B | $12.1B | ||
| Q1 25 | $12.9B | $12.1B | ||
| Q4 24 | $12.6B | $12.1B | ||
| Q3 24 | $13.3B | $11.1B | ||
| Q2 24 | $13.8B | $11.3B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.60× | 0.53× | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | 0.58× | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $-390.0M |
| Free Cash FlowOCF − Capex | $46.0M | $-461.0M |
| FCF MarginFCF / Revenue | 4.0% | -27.7% |
| Capex IntensityCapex / Revenue | 5.4% | 4.4% |
| Cash ConversionOCF / Net Profit | — | -2.62× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | $795.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-390.0M | ||
| Q4 25 | $108.0M | $650.0M | ||
| Q3 25 | $219.0M | $118.0M | ||
| Q2 25 | $237.0M | $823.0M | ||
| Q1 25 | $-4.0M | $-395.0M | ||
| Q4 24 | $177.0M | $391.0M | ||
| Q3 24 | $162.0M | $213.0M | ||
| Q2 24 | $200.0M | $-9.0M |
| Q1 26 | — | $-461.0M | ||
| Q4 25 | $46.0M | $516.0M | ||
| Q3 25 | $127.0M | $13.0M | ||
| Q2 25 | $180.0M | $727.0M | ||
| Q1 25 | $-69.0M | $-462.0M | ||
| Q4 24 | $130.0M | $277.0M | ||
| Q3 24 | $120.0M | $125.0M | ||
| Q2 24 | $166.0M | $-99.0M |
| Q1 26 | — | -27.7% | ||
| Q4 25 | 4.0% | 14.8% | ||
| Q3 25 | 11.2% | 0.4% | ||
| Q2 25 | 14.5% | 23.6% | ||
| Q1 25 | -5.8% | -16.9% | ||
| Q4 24 | 12.7% | 9.2% | ||
| Q3 24 | 11.7% | 4.5% | ||
| Q2 24 | 14.0% | -3.3% |
| Q1 26 | — | 4.4% | ||
| Q4 25 | 5.4% | 3.9% | ||
| Q3 25 | 8.1% | 3.3% | ||
| Q2 25 | 4.6% | 3.1% | ||
| Q1 25 | 5.4% | 2.5% | ||
| Q4 24 | 4.6% | 3.8% | ||
| Q3 24 | 4.1% | 3.2% | ||
| Q2 24 | 2.9% | 3.0% |
| Q1 26 | — | -2.62× | ||
| Q4 25 | — | 4.09× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | 21.55× | 5.41× | ||
| Q1 25 | -0.06× | -2.65× | ||
| Q4 24 | — | 3.18× | ||
| Q3 24 | 0.45× | 2.11× | ||
| Q2 24 | — | -0.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
HII
Segment breakdown not available.
